Phase I Study: Ivosidenib (AG-120) in Mutant < i > IDH1 < /i > Acute Myeloid Leukemia and Other Advanced Hematologic Malignancies

Slideset - Ivosidenib, an investigational mutantIDH1 inhibitor, was well tolerated with evidence of activity and durable responses in patients with malignancies harboring mutatedIDH1.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research